Altimmune (ALT) Debt Ratio (2012 - 2026)

Altimmune (ALT) posted quarterly Debt Ratio of 0.1 for Q1 2026, down 16.07% quarter-over-quarter from 0.12 in Q4 2025.

Altimmune (ALT) Debt Ratio (2012 - 2026) Analysis & Trends

Altimmune (ALT) has reported Debt Ratio for 14 consecutive years, with 0.1 the latest figure, recorded in Q1 2026.

In Q1 2026, Debt Ratio changed N/A year-over-year to 0.1; the TTM figure through Mar 2026 stood at 0.1 (changed N/A YoY), while the FY2025 annual figure was 0.12, changed N/A from the prior year.
Debt Ratio fell to 0.1 in Q1 2026 per ALT's latest filing, from 0.12 in the prior quarter.
Across five years, Debt Ratio topped out at 0.12 in Q4 2025 and bottomed at 0.01 in Q2 2022.
Historically, Debt Ratio has averaged 0.05 across 4 years, with a median of 0.03 in 2023.
On a YoY basis, Debt Ratio climbed as much as 346.72% in 2022 and fell as far as 35.77% in 2022.
Altimmune's Debt Ratio stood at 0.02 in 2022, then advanced by 16.74% to 0.03 in 2023, then soared by 373.93% to 0.12 in 2025, then dropped by 16.07% to 0.1 in 2026.
Business Quant data shows ALT's Debt Ratio at 0.1 in Q1 2026, 0.12 in Q4 2025, and 0.07 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Altimmune	571.75 Mn	571.75 Mn	-	0.07

Download Data